[1] Shrank WH, Rogstad TL, Parekh N. Waste in the US Health Care System: Estimated Costs and Potential for Savings[J]. JAMA, 2019, 322(15): 1501-1509.
[2] Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8(10): 879-907.
[3] Polaris Observatory Collaborators. HBV progress towards coverage targets[EB/OL]. (2023-09-08)[2023-11-25].https://cdafound.org/polaris-countries-dashboard/.
[4] Devarbhavi H, Asrani S K, Arab J P, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79(2): 516-537.
[5] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221.
[6] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. Endocr Pract, 2022, 28(5): 528-562.
[7] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.
[8] Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int, 2020, 14(2): 259-269.
[9] Shen T, Liu Y, Shang J, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241 e11.
[10] Lv T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(6): 1423-1434.
[11] Berg T, Krag A. The future of hepatology - "The best way to predict the future is to create it"[J]. J Hepatol, 2023, 79(2): 253-260.
[12] Pallen MJ, Loman NJ, Penn CW. High-throughput sequencing and clinical microbiology: progress, opportunities and challenges[J]. Curr Opin Microbiol, 2010, 13(5): 625-631.
[13] Kim W, Gwon Y, Park S, et al. Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration[J]. Bioact Mater, 2023, 19: 50-74.
[14] 郑涛. 医学科研成果转化率为何提不上来？这类人才不能忽视！[EB/OL].(2023-08-03)[2023-11-25].http://zgyjw.org.cn/news/8594.html.
[15] 窦晓光,徐小元,南月敏,等. 2022年肝脏疾病研究进展[J]. 中华肝脏病杂志, 2023, 31(1): 3-15.
[16] Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review[J]. JAMA Oncol, 2021, 7(1): 113-123.
[17] Gray E, Norris S, Schmitz S, et al. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?[J]. J Comp Eff Res, 2017, 6(1): 65-82.
[18] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41 (01): 3-28.
[19] Su S, Wong WC, Zou Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation[J]. Lancet Glob Health, 2022, 10(2): e278-e287.
[20] Lee YT, Fujiwara N, Yang JD, et al. Risk stratification and early detection biomarkers for precision HCC screening[J]. Hepatology, 2023, 78(1): 319-362. |
